Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

Friday, June 26, 2026Robert BarrieView original

Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage.

Read the full article on the original site.